



Title	Urine Test Reagent for Cancer Screen and Monitoring
Agency	MaHTAS, Health Technology Assessment Section, Ministry of Health Malaysia Level 4, Block E1, Parcel E, Presint 1, Federal Government Administrative Center, 62590 Putrajaya, Malaysia; Tel: +60 3 88 83 12 29, Fax: +60 3 88 83 12 30; htamalaysia@moh.gov.my, www.moh.gov.my
Reference	Technology Review Report, 019/07, 2007. http://medicaldev.moh.gov.my/uploads/urine%20test.pdf

Aim

To determine the safety, effectiveness, and cost effectiveness of urine test reagent for cancer (URC) in cancer screening and monitoring.

Conclusions and results

There is insufficient evidence regarding the safety, effectiveness, and cost effectiveness of URC.

Methods

Literature was searched via electronic databases, including PubMed, Ovid, ProQuest, Ebscohost, EBM Reviews for Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Clinical Trial Registry, Science Direct, Springer Link, INAHTA databases, and general databases such as Google and Yahoo.

The search strategy used the terms, either alone or in combination: "URC" OR "urine-test reagent" OR "urin* metabolites" OR "5-hydroxyindole" OR "p-hydroxyphenylpyruvic acid", cancer OR carcinoma OR carcinoid, effectiveness OR efficacy, safety OR safe OR "adverse effect*" OR "harm* effect*" OR "toxicity", "cost effectiveness" OR "cost analysis" OR econom*. There were no limitations in the search. The distributor URC Global Sdn. Bhd also provided literature.

All relevant literature was critically appraised and the evidence level graded according to the Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2001).

Further research/reviews required

More clinical research is needed to evaluate safety and effectiveness.